GSK plc Statement on Zantac (ranitidine) Litigation

GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Boyd/Steenvoord, resolving the case filed in California state court. The case, which was set to begin trial on 2 April 2024, will be dismissed. The settlement reflects the Company’s desire to avoid the distraction related to protracted litigation in this case. GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at

GSK enquiries
Media:Tim Foley+44 (0) 20 8047 5502(London)
Dan Smith+44 (0) 20 8047 5502(London)
Kathleen Quinn+1 202 603 5003(Washington DC)
Lyndsay Meyer+1 202 302 4595(Washington DC)
Investor Relations:Nick Stone+44 (0) 7717 618834(London)
James Dodwell+44 (0) 20 8047 2406(London)
Mick Readey+44 (0) 7990 339653(London)
Josh Williams+44 (0) 7385 415719(London)
Camilla Campbell+44 (0) 7803 050238(London)
Steph Mountifield+44 (0) 7796 707505(London)
Jeff McLaughlin+1 215 751 7002(Philadelphia)
Frannie DeFranco+1 215 751 4855(Philadelphia)
Back to All News All Market News

Sign up for our Stock News Highlights

Delivered to your inbox every Friday